ADL launches PolypDx urine test for precancerous colorectal polyps

Philadelphia-based Atlantic Diagnostic Laboratories has launched PolypDx, a noninvasive urine test that detects precancerous adenomatous colorectal polyps, according to a press release.

The test requires only a small urine sample, and patients who test positive can then be referred for a colonoscopy to have their adenomatous polyps safely removed before progression to colorectal cancer.

The launch follows a multi-million-dollar agreement with Canada’s Metabolomic Technologies Inc. granting ADL exclusive licensing and distribution rights to market PolypDx in the U.S.

“The partnership and collaboration between MTI and [ADL] will provide the opportunity for patients to access a simple and accurate test with proven capacity to detect adenomatous colonic polyps and thereby prevent colon cancer,” Richard Fedorak, MD, President of MTI, said in the press release.

A clinical trial in Canada involving almost 1,000 patients showed PolypDx detected adenomatous polyps with greater sensitivity than currently available stool tests, according to the press release.

“Colorectal cancer is a leading cause of death in the United States. With early detection in the adenomatous polyp stage, this form of cancer is preventable,” Aaron Domenico, COO of ADL, said in the press release.

Disclosures: Domenico is employed by ADL and Fedorak is employed by MTI.